ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

cebranopadol

Also written as “GRT6005”, “Cebranopadol” and “Cebranopadol 600 µg”.

Its studies are mostly in Pain · Chronic Pain · Acute Pain · Substance-Related Disorders · Osteoarthritis, led by 2 companies.

Drug pageCebranopadol: every studyAll 18 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 7, 201318 company-led studies, 2 open or runningNext primary completion: Jan 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Tris Pharma160 open or runningphase 3since Oct 7, 2013Mar 24, 2009none ahead
Adneuris Therapeuticsits history only22 open or runningphase 3since Sep 22, 2026Sep 22, 2026Jan 2027phase 3 · NCT07845071

Also a collaborator on its studies: AbbVie.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Tris Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Mar 24, 2009.

  1. Apr 3, 2009Phase 2 study in Diabetic NeuropathiesNCT00878293 · 90 enrolled · Germany, United Kingdom
  2. May 2, 20112 phase 2 studiesNCT01347671, NCT01357837
  3. Oct 16, 2012Phase 2 study in OsteoarthritisNCT01709214 · 619 enrolled · United States
  4. Nov 8, 2012Phase 2 study in Low Back PainNCT01725087 · 1,089 enrolled · Austria, Belgium, Denmark and more
  5. Sep 6, 2013Phase 2 study in Chronic PainNCT01939366 · 699 enrolled · United States, Austria, Denmark and more
  6. Oct 7, 2013Phase 3 study in PainNCT01964378 · 200 enrolled · Austria, Belgium, Bulgaria and more
  7. Dec 12, 2013Phase 3 study in PainNCT02031432 · 76 enrolled · Austria, Belgium, Bulgaria and more
  8. Mar 18, 2019Phase 1 study in PharmacokineticNCT03882762 · 34 enrolled · United States
  9. May 20, 2019Phase 1 study in Prolonged QTc IntervalNCT03958123 · 171 enrolled · United States
  10. Feb 16, 2022Phase 1 study in PainNCT05256108 · 38 enrolled · United States
  11. Jul 27, 2022Phase 1 study in PainNCT05491785 · 30 enrolled · Netherlands
  12. May 16, 2024Phase 3 study in Acute PainNCT06423703 · 240 enrolled · United States
  13. Jun 5, 2024Phase 1 study in Substance-Related DisordersNCT06453265 · 48 enrolled · United States
  14. Aug 6, 2024Phase 3 study in Acute PainNCT06545097 · 279 enrolled · United States

TargetBeta

“An orally available benzenoid that acts as an opioid peptide receptor agonist for the nociceptin/orphanin FQ peptide receptor (opioid receptor like -1; OPRL1; ORL-1; NOP; kappa-type 3 opioid receptor) and the classical opioid receptors, mu, delta and kappa, ”NCIt, by rule
“Nociceptin receptor agonist; Opioid receptors; mu/kappa/delta agonist”ChEMBL 37, by rule

Studies

All 16 Tris Pharma leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06545097Acute Pain · United States3CompletedDec 30, 2024279
NCT06453265Substance-Related Disorders · United States1CompletedNov 6, 202448
NCT06423703Acute Pain · United States3CompletedJan 31, 2025240
NCT05491785Pain · Netherlands1CompletedMar 30, 202330
NCT05256108Pain · United States1CompletedJul 12, 202238
NCT03958123Prolonged QTc Interval · United States1CompletedNov 27, 2013171
NCT03882762Pharmacokinetic · United States1CompletedSep 17, 201434
NCT02031432Pain · Austria, Belgium, Bulgaria and more3CompletedApr 201676
NCT01964378Pain · Austria, Belgium, Bulgaria and more3TerminatedOct 16, 2015200
NCT01939366Chronic Pain · United States, Austria, Denmark and more2CompletedJan 2015699
NCT01725087Low Back Pain · Austria, Belgium, Denmark and more2CompletedJul 20141,089
NCT01709214Osteoarthritis · United States2CompletedApr 2014619
NCT01357837Osteoarthritis, Knee · Austria, Poland, Spain2CompletedDec 2011207
NCT01347671Pain · Bulgaria, Germany, Romania2CompletedJan 2012189
NCT00878293Diabetic Neuropathies · Germany, United Kingdom2CompletedMay 201090
NCT00872885Pain, Postoperative · United States2CompletedAug 2009258

How it is read

Names in the registry

  • “GRT6005”, 8 entries
  • “Cebranopadol”, 5 entries
  • “Cebranopadol 600 µg”, 3 entries
  • “Cebranopadol 400 ug”, 2 entries
  • “Cebranopadol 1000 µg”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.